Standout Papers
- Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200 (2007)
- American Society of Clinical Oncology Guideline Recommendations for Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer (2005)
- American Society of Clinical Oncology Recommendations on Adjuvant Chemotherapy for Stage II Colon Cancer (2004)
- Sentinel Lymph Node Biopsy for Patients With Early-Stage Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update (2014)
- Radioembolization for Hepatocellular Carcinoma Using Yttrium-90 Microspheres: A Comprehensive Report of Long-term Outcomes (2009)
- Gemcitabine Alone Versus Gemcitabine Plus Radiotherapy in Patients With Locally Advanced Pancreatic Cancer: An Eastern Cooperative Oncology Group Trial (2011)
- Phase III Study of Gemcitabine in Combination With Fluorouracil Versus Gemcitabine Alone in Patients With Advanced Pancreatic Carcinoma: Eastern Cooperative Oncology Group Trial E2297 (2002)
- Fluorouracil vs Gemcitabine Chemotherapy Before and After Fluorouracil-Based Chemoradiation Following Resection of Pancreatic Adenocarcinoma (2008)
- Recommendations for Radioembolization of Hepatic Malignancies Using Yttrium-90 Microsphere Brachytherapy: A Consensus Panel Report from the Radioembolization Brachytherapy Oncology Consortium (2007)
- Y90 Radioembolization Significantly Prolongs Time to Progression Compared With Chemoembolization in Patients With Hepatocellular Carcinoma (2016)
- Long-Term Update of US GI Intergroup RTOG 98-11 Phase III Trial for Anal Carcinoma: Survival, Relapse, and Colostomy Failure With Concurrent Chemoradiation Involving Fluorouracil/Mitomycin Versus Fluorouracil/Cisplatin (2012)
- Financial toxicity in cancer care: Prevalence, causes, consequences, and reduction strategies (2019)
- Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211) (2022)
Immediate Impact
1 by Nobel laureates 3 from Science/Nature 155 standout
Citing Papers
Colorectal cancer
2024 Standout
[177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2–3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study
2024 Standout
Works of Al B. Benson being referenced
Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211)
2022 Standout
A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: A trial of the ECOG-ACRIN Cancer Research Group (E2211).
2018
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Al B. Benson | 18591 | 8507 | 8504 | 487 | 30.3k | |
| Leonard B. Saltz | 27418 | 10097 | 9385 | 533 | 37.4k | |
| Michel Ducreux | 25207 | 11207 | 10305 | 612 | 36.6k | |
| Malcolm J. Moore | 24529 | 9275 | 10385 | 354 | 36.2k | |
| Jean‐Luc Raoul | 11767 | 5825 | 5646 | 341 | 25.6k | |
| Olivier Bouché | 18148 | 7789 | 9242 | 410 | 24.6k | |
| Timothy M. Pawlik | 14581 | 13154 | 8516 | 682 | 28.0k | |
| Filippo de Braud | 17473 | 5482 | 8522 | 749 | 26.0k | |
| John D. Hainsworth | 21144 | 5165 | 12105 | 623 | 36.4k | |
| Bengt Glimelius | 29523 | 17485 | 9594 | 690 | 40.5k | |
| Robert A. Wolff | 21227 | 9068 | 8251 | 455 | 28.2k |
All Works
Login with ORCID to disown or claim papers
Loading papers...